---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Cost assumptions"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Cost assumptions. Topics: Cretostimogene grenadenorepvec dosing schedule in BOND-003, Nadofaragene firadenovec wholesale acquisition cost, Nadofaragene firadenovec dosing, Nogapendekin alfa inbakicept wholesale acquisition cost, and 14 further topics. 18 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics/cost-assumptions"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Cost assumptions

<a id="heading-4.2.4"></a>

## 4.2.4 Cost Assumptions

<a id="topic-4.2.4-1"></a>

### Budget impact model of cretostimogene grenadenorepvec: cost assumptions

No evidence found.

<a id="topic-4.2.4-2"></a>

### Cretostimogene grenadenorepvec price

No evidence found.

<a id="topic-4.2.4-3"></a>

### Cretostimogene grenadenorepvec dosing schedule in BOND-003

> “The initial induction course of therapy is six weekly doses of cretostimogene”
> “Patients who achieve a CR at month three receive maintenance treatments, involving three weekly cretostimogene doses administered at the same concentration every three months for the first 12 months and every six months for the next 24 months.”
> “Patients who do not achieve a CR after the first induction course may receive a second induction course of six weekly cretostimogene treatments at month 3, rather than the maintenance course involving three weekly treatments.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-4.2.4-4"></a>

### Nadofaragene firadenovec wholesale acquisition cost

| Field | Value |
| --- | --- |
| NDC | “55566-1050-01” |
| Dosage form | “box” |
| Pack size | “4 vials x 20 ml” |
| WAC | “$62,740.70” |

Source: [Ferring Adstiladrin Connecticut WAC disclosure (2026)](https://ferringusa.com/Connecticut-Adstiladrin-WAC-Pricing-Sheet)

> “This above pricing information is being provided pursuant to Connecticut House Bill Substitute No. 6669 and is accurate as of October 2, 2026.”

Source: [Ferring Adstiladrin Connecticut WAC disclosure (2026)](https://ferringusa.com/Connecticut-Adstiladrin-WAC-Pricing-Sheet)

<a id="topic-4.2.4-5"></a>

### Nadofaragene firadenovec dosing

> “instilled once every three (3) months into the bladder via a urinary catheter”
> “If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.”

Source: [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download)

<a id="topic-4.2.4-6"></a>

### Nogapendekin alfa inbakicept wholesale acquisition cost

| Field | Value |
| --- | --- |
| Marketed product | “ANKTIVA 400 mcg/0.4 mL” |
| NDC | “81481-803-01” |
| WAC price (400 mcg/0.4 mL vial) | “$35,800.00” |

Source: [ImmunityBio Anktiva Colorado WAC disclosure (2025)](https://immunitybio.com/wp-content/uploads/2025/06/Anktiva-Colorado-Disclosure-FINAL.pdf)

> “WAC does not reflect discounts, rebates and other reductions in price.”
> “Data as of: January 1, 2025”

Source: [ImmunityBio Anktiva Colorado WAC disclosure (2025)](https://immunitybio.com/wp-content/uploads/2025/06/Anktiva-Colorado-Disclosure-FINAL.pdf)

<a id="topic-4.2.4-7"></a>

### Nogapendekin alfa inbakicept dosing

> “For induction: ANKTIVA is recommended at a dose of 400 mcg administered intravesically with BCG once a week for 6 weeks.”
> “For maintenance: After BCG and ANKTIVA induction therapy, ANKTIVA is recommended at a dose of 400 mcg administered intravesically with BCG once a week for 3 weeks at months 4, 7, 10, 13 and 19 (for a total of 15 doses).”
> “For patients with no evidence of high-grade disease at month 25 and later, maintenance instillations with BCG may be administered once a week for 3 weeks at months 25, 31, and 37 for a maximum of 9 additional instillations.”

Source: [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf)

<a id="topic-4.2.4-8"></a>

### Pembrolizumab list price

> “for each indicated dose of KEYTRUDA when given every 3 weeks is $12,517.44.”
> “The list price for each indicated dose of KEYTRUDA when given every 6 weeks is $25,034.88.”
> “The list price is also referred to as wholesale acquisition cost or WAC.”
> “The list price does not include other treatment-related costs. The list price is current as of September 2026.”

Source: [Merck KEYTRUDA cost information (2026)](https://www.keytruda.com/financial-support/)

<a id="topic-4.2.4-9"></a>

### Pembrolizumab dosing in BCG-unresponsive NMIBC

> “Until persistent or recurrent high-risk NMIBC, disease progression, unacceptable toxicity, or up to 24 months”
> “Patients received KEYTRUDA 200 mg every 3 weeks until unacceptable toxicity, persistent or recurrent high-risk NMIBC, or progressive disease.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-4.2.4-10"></a>

### Gemcitabine intravesical system wholesale acquisition cost

No evidence found.

<a id="topic-4.2.4-11"></a>

### Gemcitabine intravesical system dosing

> “Insert INLEXZO (225 mg of gemcitabine) into the bladder once every 3 weeks for up to 6 months (8 doses), followed by once every 12 weeks for up to 18 months (6 doses), or until persistent or recurrent NMIBC, disease progression, or unacceptable toxicity.”

Source: [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf)

<a id="topic-4.2.4-12"></a>

### Medicare Part B payment limits for comparator agents, fourth quarter of 2026

> “Effective October 1, 2026 through December 31, 2026”
> “Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data.”

Source: [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

| HCPCS code and product | Short description | HCPCS code dosage | Payment limit (USD) | Coinsurance percentage |
| --- | --- | --- | --- | --- |
| J9029 nadofaragene firadenovec (Adstiladrin) | “Instill adstiladrin, tx dose” | “PER THERAPEUTIC DOSE” | “65200.563” | “20.000” |
| J9028 nogapendekin alfa inbakicept (Anktiva) | “Inj, nogapendekin pmln, 1mcg” | “1 MCG” | “94.139” | “20.000” |
| J9183 gemcitabine intravesical system (Inlexzo) | “Gemcitabine intravesical sys” | “225 MG” | “73054.053” | “20.000” |
| J9271 pembrolizumab (Keytruda) | “Inj pembrolizumab” | “1 MG” | “62.253” | “20.000” |
| J9030 BCG live intravesical | “Bcg live intravesical 1mg” | “1 MG” | “3.532” | “20.000” |
| J9357 valrubicin | “Valrubicin injection” | “200 MG” | “1230.664” | “20.000” |
| J9201 gemcitabine | “In gemcitabine hcl nos 200mg” | “200 MG” | “2.734” | “20.000” |
| J9171 docetaxel | “Docetaxel injection” | “1 MG” | “0.471” | “20.000” |
| J9280 mitomycin | “Mitomycin injection” | “5 MG” | “34.838” | “20.000” |

Source: [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

<a id="topic-4.2.4-13"></a>

### Medicare physician fee schedule relative value units for office-based instillation, surveillance, and evaluation services, 2026

> “2026 National Physician Fee Schedule Relative Value File October Release”
> “RELEASED 08/26/2026”

Source: [CMS Physician Fee Schedule Relative Value File (2026)](https://www.cms.gov/files/zip/rvu26d-updated-08-26-2026.zip)

| CPT code | Description | Non-facility total RVU | Facility total RVU | Conversion factor |
| --- | --- | --- | --- | --- |
| 51720 | “Treatment of bladder lesion” | “2.75” | “1.14” | “33.4009” |
| 51701 | “Insert bladder catheter” | “1.36” | “0.66” | “33.4009” |
| 52000 | “Cystourethroscopy” | “6.46” | “2.13” | “33.4009” |
| 52204 | “Cystoscopy w/biopsy(s)” | “10.64” | “3.80” | “33.4009” |
| 88112 | “Cytopath cell enhance tech” | “1.96” | “1.96” | “33.4009” |
| 88120 | “Cytp urne 3-5 probes ea spec” | “16.23” | “16.23” | “33.4009” |
| 74178 | “Ct abd&plv wo cntr flwd cntr” | “10.12” | “10.12” | “33.4009” |
| 99214 | “Office o/p est mod 30 min” | “4.06” | “2.53” | “33.4009” |

Source: [CMS Physician Fee Schedule Relative Value File (2026)](https://www.cms.gov/files/zip/rvu26d-updated-08-26-2026.zip)

<a id="topic-4.2.4-14"></a>

### Medicare physician fee schedule relative value units for transurethral resection and radical cystectomy, 2026

| CPT code | Description | Facility total RVU | Global days | Conversion factor |
| --- | --- | --- | --- | --- |
| 52234 | “Cystoscopy and treatment” | “6.49” | “000” | “33.4009” |
| 52235 | “Cystoscopy and treatment” | “7.62” | “000” | “33.4009” |
| 52240 | “Cystoscopy and treatment” | “10.31” | “000” | “33.4009” |
| 51570 | “Removal of bladder” | “39.05” | “090” | “33.4009” |
| 51575 | “Removal of bladder & nodes” | “48.18” | “090” | “33.4009” |
| 51590 | “Remove bladder/revise tract” | “51.25” | “090” | “33.4009” |
| 51595 | “Remove bladder/revise tract” | “57.93” | “090” | “33.4009” |
| 51596 | “Remove bladder/create pouch” | “62.52” | “090” | “33.4009” |

Source: [CMS Physician Fee Schedule Relative Value File (2026)](https://www.cms.gov/files/zip/rvu26d-updated-08-26-2026.zip)

<a id="topic-4.2.4-15"></a>

### Unit cost inputs in a published budget impact model

> “The unit cost for nadofaragene firadenovec was $60,000.00 per instillation based on the average wholesale acquisition cost from Truven Redbook Online database (now Merative Micromedex Redbook Online)”
> “with an administration cost per instillation of $42.90 based on the Centers for Medicare & Medicaid Services (CMS) Physician Fee Schedule”
> “The monthly recurrence cost of $2,723.10 was obtained from Yang et al. (2021)”
> “The monthly progression cost of $6,004.60 was also obtained from Yang et al. (2021)”
> “The unit cost associated with cystectomy, including the cystectomy procedure cost and 90-day direct hospital costs, was estimated to be $46,646 based on Leow et al.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.2.4-16"></a>

### Three-month Medicare costs in a published cost-effectiveness model, 2024

| Item | 3 month cost (USD) | Range |
| --- | --- | --- |
| Radical cystectomy without complications | “15850” | “14439–16472” |
| Radical cystectomy with major complications | “37330” | “36275–37952” |
| Pembrolizumab, 200 mg every 3 weeks | “46356” | “0–250,000” |
| Gemcitabine-docetaxel induction | “828” | “0–250,000” |
| Gemcitabine-docetaxel maintenance | “414” | “0–250,000” |
| Nadofaragene, 75 mL every 3 months | “63594” | “0–250,000” |
| Nogapendekin alfa inbakicept-BCG induction | “216189” | “0–250,000” |
| Nogapendekin alfa inbakicept-BCG maintenance | “108095” | “0–250,000” |
| Recurrence, initial cost (TURBT, office visit) | “3779” | “2070–5539” |
| Surveillance on bladder-sparing therapy | “3638 per year” | “3384–7284” |

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

> “We calculated 2024 U.S. healthcare costs from a Medicare payer perspective. Costs were obtained for drugs, procedures, tests, and hospital admissions through Medicare payment schedules for CPT, DRG, and HCPCS codes (Table 2).”

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

<a id="topic-4.2.4-17"></a>

### Treatment cost sources in a published cost-per-responder model

> “Initial and subsequent treatment costs were derived from the average sales price (ASP) pricing file with TAR-200 pricing based on the IBM Micromedex RED BOOK wholesale acquisition cost, as ASP pricing was not yet available at the time of this study; generic costs were selected for valrubicin”
> “Over the 15-month model time horizon, excluding NAI+BCG reinduction, the total cost per patient treated with TAR-200 was $823,824, compared with $485,781 for pembrolizumab, $504,487 for NF, $731,075 for NAI+BCG, and $347,861 for valrubicin.”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

<a id="topic-4.2.4-18"></a>

### Placeholder drug prices in the ICER review

> “Since the prices for nadofaragene firadenovec and oportuzumab monatox were not available at the time of the report, the price for nadofaragene firadenovec was set to equal the annual price of pembrolizumab ($164,337), whereas oportuzumab was set at $150,000 per year net of all rebates based on analyst estimates.”

Source: [Beinfeld et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391138/)

<a id="topic-4.2.4-19"></a>

### Costs of care after BCG with and without progression

> “Total mean annualized costs per patient after BCG among those who progressed [$65,668 (SD $53,943)] were more than double compared with patients who did not [$29,780 ($36,425)].”
> “Annualized HRU and mean medical costs (2020 United States dollars) were estimated and compared between patients with versus without progression.”

Source: [Yang et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33543424/)

<a id="topic-4.2.4-20"></a>

### Costs of radical cystectomy in United States claims data

> “Median [IQR] per-patient costs were $70,671 [$55,878-$106,812] for the RC cohort at 90-days follow-up and rose to $211,671 [$138,597-$346,389] by 5-years post-index.”

Source: [Williams et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40122296/)

<a id="topic-4.2.4-21"></a>

### Five-year surveillance costs by NMIBC risk group

> “Cumulative costs of care over a 5-year period were $52,125 for low-risk, $146,250 for intermediate-risk, and $366,143 for high-risk NMIBC.”

Source: [Mossanen et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30446799/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
